Understanding how non-classical RAS proteins contribute to cancer growth
Official title: Regulation and tumorigenesis of non-classical RAS oncoproteins - Resubmission
Funded at New York University School of Medicine · NIH-11003762 · Data updated 2026-11-12
This study is looking at how certain proteins linked to cancer growth work and how they might be targeted to create new treatments, especially for bladder cancer, so that patients can have better options for their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $543,820 |
| NIH project number | 5R01CA279171-02 |
| Project ID | NIH-11003762 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with bladder cancer or other cancers associated with non-classical RAS protein dysregulation.
✕Less likely to help
Patients with cancers not related to RAS proteins or those without active cancer may not benefit from this research.
What this research studies
This research investigates the role of non-classical RAS oncoproteins in cancer development, focusing on how these proteins affect cell growth and survival. The team aims to uncover the mechanisms by which these proteins are regulated and how their dysregulation contributes to tumorigenesis. By studying the interactions and pathways involving these proteins, the research seeks to identify potential therapeutic targets for treating various cancer subtypes, particularly bladder cancer. Patients may benefit from new treatment strategies that arise from a better understanding of these oncoproteins.
Why it matters
Potential benefit: If successful, this research could lead to novel therapies that specifically target non-classical RAS proteins, improving treatment options for patients with certain types of cancer.
How similar studies have gone: While the role of classical RAS proteins in cancer has been extensively studied, the investigation of non-classical RAS proteins is relatively novel, indicating a potential for groundbreaking findings.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Castel, Pau — New York University School of Medicine
- Study coordinator: Castel, Pau
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.